title: Valganciclovir therapy for immune recovery uveitis complicated by macular edema.
abstract: OBJECTIVE
  To determine whether treatment with valganciclovir will improve visual acuity in eyes with immune recovery uveitis complicated by macular edema.
  
  
  METHODS
  Prospective open label controlled Phase II drug study.
  
  
  METHODS
  Five patients with chronic macular edema as a result of immune recovery uveitis were studied. Baseline fluorescein angiograms, best-corrected ETDRS visions, and cytomegalovirus (CMV) lymphoproliferative T-cell function assays were obtained and repeated after three months of valganciclovir therapy (900 mg daily) and again three months after withdrawal of therapy.
  
  
  RESULTS
  Vision improved by a mean of 11 letters in the treatment phase (P =.05). Graded angiograms showed three patients had treatment reduction of macular edema. One patient had rebound increase in macular edema after the withdrawal phase. The CMV lymphoproliferative response was not affected by the valganciclovir.
  
  
  CONCLUSIONS
  Results suggest valganciclovir treatment may benefit visual acuity in patients with macular edema from immune recovery uveitis.
authors.affiliation: UCSD Jacobs Retina Center, Department of Ophthalmology, Shiley Eye Center, La Jolla, California 92093, USA.
authors.forename: Brian R
authors.initials: BR
authors.lastname: Kosobucki
authors.forename: Daniel E
authors.initials: DE
authors.lastname: Goldberg
authors.forename: Kenichiro
authors.initials: K
authors.lastname: Bessho
authors.forename: Hyoung J
authors.initials: HJ
authors.lastname: Koh
authors.forename: Nuttawut
authors.initials: N
authors.lastname: Rodanant
authors.forename: Laurie
authors.initials: L
authors.lastname: Labree
authors.forename: Lingyun
authors.initials: L
authors.lastname: Cheng
authors.forename: Rachel D
authors.initials: RD
authors.lastname: Schrier
authors.forename: Stanley P
authors.initials: SP
authors.lastname: Azen
authors.forename: William R
authors.initials: WR
authors.lastname: Freeman
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy / Q000276:immunology; D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D000998:Antiviral Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D017726:Cytomegalovirus Retinitis / Q000188:drug therapy / Q000276:immunology; D005260:Female; D005451:Fluorescein Angiography; D015774:Ganciclovir / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D006801:Humans; D007107:Immune System / Q000502:physiology; D008269:Macular Edema / Q000150:complications / Q000188:drug therapy*; D008297:Male; D011446:Prospective Studies; D014605:Uveitis / Q000188:drug therapy* / Q000209:etiology; D000077562:Valganciclovir; D014792:Visual Acuity / Q000187:drug effects
chemical_list: D000998:Antiviral Agents; D000077562:Valganciclovir; D015774:Ganciclovir